OncoMatch/Clinical Trials/NCT06096779
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Is NCT06096779 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab · Bevacizumab — The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
Cannot have received: immune checkpoint blockade therapy
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
Cannot have received: systemic immunostimulatory agent
Treatment with systemic immunostimulatory agents
Cannot have received: systemic immunosuppressive medication
Treatment with systemic immunosuppressive medication
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Cannot have received: locoregional therapy to liver
Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support; Platelet count ≥ 50 × 10^9/L (50,000/μL) without transfusion; Hemoglobin ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
Kidney function
Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
Liver function
Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment; AST and ALT ≤ 5 × ULN; Serum bilirubin ≤ 3 × ULN; Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months; INR ≤2.3
Adequate hematologic and end-organ function Absolute neutrophil count ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support Platelet count ≥ 50 × 10^9/L (50,000/μL) without transfusion Hemoglobin ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL]) AST and ALT ≤ 5 × ULN Serum bilirubin ≤ 3 × ULN Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula) Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months International normalized ratio (INR) ≤2.3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- University of Southern California-Keck School of Medicine -1975 Zonal Ave · Los Angeles, California
- University of Southern California · Newport Beach, California
- University of California Irvine Medical Center · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06096779 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages